Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro
Peter Kolbinger1, Michael Gruber2, Gabriel Roth2
1Clinic of Radiology, Minimally Invasive Therapies and Nuclear Medicine, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.
Abstract:
Candidemia is frequent in critically ill patients, especially in combination with an acute kidney injury (AKI). Echinocandins generally are recommended for therapy of such infections. Recent studies found no need for dosage adjustment in patients with end-stage renal disease receiving hemodialysis, or patients with AKI receiving continuous venovenous hemofiltration. The aim of this in vitro study was to examine the adsorption of anidulafungin to the surface of the hemofilter during continuous venovenous hemodialysis (CVVHD) and its effect on anidulafungin concentrations. The concentration of anidulafungin in the dialyzed fluid, and the dialysate during CVVHD in vitro was examined using three different dialyzed fluids (saline; saline with 40 g/L human albumin; and a mixture of human erythrocytes and fresh frozen plasma). After the end of dialysis, the hemofilter was opened and portions of the filter capillaries were also analyzed to determine the amount of anidulafungin adsorbed. When dialyzing saline, about 99% of the anidulafungin used adsorbed to the hemofilter capillaries; in the experiments with saline with 40 g/L albumin, about 60% adsorbed to the hemofilter's surface, and when blood was dialyzed, 35% was found adsorbed after analyzing the filter capillaries. Anidulafungin was not detectable in the dialysate of any of the experiments, consequently the dialysis clearance was 0 mL/min. In conclusion, during CVVHD in vitro we found remarkable adsorption of anidulafungin to the hemofilter's surface, yet the effect on the tissue concentration needs further examination.
Insights
Anidulafungin significantly adsorbs to hemofilters during continuous venovenous hemodialysis (CVVHD) in vitro. This adsorption may impact drug concentrations, necessitating further investigation into tissue levels for critically ill patients with acute kidney injury (AKI).
Area of Science:
- Pharmacology
- Nephrology
- Critical Care Medicine
Background:
- Candidemia is common in critically ill patients, often co-occurring with acute kidney injury (AKI).
- Echinocandins are standard treatment, but their behavior during renal replacement therapy requires clarification.
- Previous studies suggested no dose adjustment for anidulafungin in end-stage renal disease or continuous venovenous hemofiltration.
Purpose of the Study:
- To investigate the in vitro adsorption of anidulafungin to hemofilter surfaces during continuous venovenous hemodialysis (CVVHD).
- To assess the impact of this adsorption on anidulafungin concentrations in dialyzed fluids and dialysate.
Main Methods:
- In vitro study simulating CVVHD using anidulafungin.
- Tested three dialyzing fluids: saline, saline with albumin, and blood (erythrocytes and plasma).
- Measured anidulafungin concentrations in dialysate and analyzed hemofilter capillaries for adsorbed drug.
Main Results:
- High adsorption rates observed: ~99% in saline, ~60% with albumin, and ~35% in blood.
- Anidulafungin was undetectable in the dialysate across all experiments.
- Dialysis clearance of anidulafungin was determined to be 0 mL/min in vitro.
Conclusions:
- Significant in vitro adsorption of anidulafungin to hemofilters occurs during CVVHD.
- The clinical relevance of this adsorption on actual tissue drug concentrations warrants further investigation.
- Current findings highlight a potential pharmacokinetic interaction during renal replacement therapy.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemodialysis I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Dialysis
Hemodialysis II: Procedure and Complications


